UNLOCK Power. ADD NEXLIZET.

NEXT-LEVEL NEXLIZET IS A HIGHLY EFFICACIOUS, ORAL, NONSTATIN,
LDL-C LOWERING ADD-ON THERAPY1,2

When patients with ASCVD and/or HeFH need additional LDL-C lowering on top of diet and maximally tolerated statin therapy, adding NEXLIZET can get them significantly lower1

Significant LDL-C reductions in 053 Trial for patients taking maximally tolerated statins1,3

Mean 38% LDL-C reduction vs placebo

ADD NEXLIZET TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY1

Significant 38% mean LDL-C reduction
vs placebo at Week 12

LDL-C changes from baseline (LS mean; P<0.001):

  • NEXLIZET: -36% (n=86)

  • placebo: +2% (n=41)

LDL-C changes from baseline (LS mean)
for other drugs in the trial:

  • bempedoic acid: -17% (n=88)

  • ezetimibe: -23% (n=86)

LDL-C changes from baseline (LS mean; P<0.001):
  • NEXLIZET: -36% (n=86)
  • placebo: +2% (n=41)
LDL-C changes from baseline (LS mean) for other drugs in the trial:
  • bempedoic acid: -17% (n=88)
  • ezetimibe: -23% (n=86)

Consistent efficacy has been observed across a range of statin intensities.4




NEXLIZET: MAXIMUM LDL-C LOWERING EFFECT WAS OBSERVED AT WEEK 41

Maximum LDL-C lowering effect was observed at Week 4

053 Trial (Study 1) was a 12-week, randomized, double-blind, Phase 3 trial in 301 patients randomized 2:2:2:1 to receive NEXLIZET (n=86), bempedoic acid (n=88), ezetimibe (n=86), or placebo (n=41). 053 Trial included patients aged ≥18 years with fasting LDL-C ≥100 mg/dL if they had ASCVD and/or HeFH, or ≥130 mg/dL if they had multiple CV risk factors. Therapies were added to whatever patient’s maximally tolerated statin dose was (including no statin at all). Primary endpoint was % change from baseline to Week 12 in LDL-C. Secondary endpoint was % change from baseline to Week 12 in hsCRP, non-HDL-C, total C, apolipoprotein B, HDL-C, and TGs.1,3

ASCVD=atherosclerotic cardiovascular disease; CV=cardiovascular; HeFH=heterozygous familial hypercholesterolemia; hsCRP=high-sensitivity C-reactive protein; LDL-C=low-density lipoprotein cholesterol; LS=least squares; non-HDL-C=non-high-density lipoprotein cholesterol; TGs=triglycerides; total C=total cholesterol.

References: 1. NEXLIZET. Prescribing information. Esperion Therapeutics, Inc.; 09/2021. 2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. 3. Data on file. CSR 1002-053. January 2019. 4. Data on file. Esperion 053 Ad-hoc Tables Excluding 3 Sites. March 2019.

SEE NEXLIZET SAFETY Results